USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Merck Sharp & Dohme B.V.

USPTO PatentsView assignee record - 34 granted patents across 23 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Merck ranks #9,318 of 49,997 tracked US assignees by granted-patent volume, with 34 patents across 23 technology areas.

#9,318
of 49,997 US assignees by volume
Top 38%
by Innovation Score (39.4/100)
15.8
avg claims per patent
-64%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R9318 · Foreign Corporation #9,318 · 34 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-SMALL 34 grants
  • UPPER-Q #9,318/49,997
  • PHOTO-FINISH Lund
  • CPC-FOCUS A61P · 23 areas
  • INNOV-THIN 39.4/100
  • CLAIMS-RICH 15.8 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -64% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Lund, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Merck’s 39.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Merck

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Merck's Innovation Score is 39.4/100 (top 38% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Merck?

Each dot is one of Merck’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Merck’s own 15.8 claims/patent is at or below the 17.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Merck vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 33.934.034.03434.034.034.1 5101520253035 Granted patents (volume) Avg claims / patent Lund, Inc. - 34, 18LundLutonix, Inc. - 34, 17.79LutonixLytro, Inc. - 34, 30.09LytroMagnacom Ltd. - 34, 20.59MagnacomMianyang HKC Optoelectronics Technology Co., Ltd - 34, 15.32Mianyang HKC Opto…Mikuni Electron Corporation - 34, 16.41Mikuni ElectronMobiletron Electronics Co., Ltd. - 34, 9.24MobiletronMold-masters (2007) Limited - 34, 18.94Mold-masters (200…Merck Sharp & Dohme B.V. - 34, 15.85Merck Sharp & Doh…
Merck vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Merck's grants concentrate

Merck Sharp & Dohme B.V. is a focused PatentsView assignee: 23 CPC subclasses with 67.6% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (10 grants) versus a trough of 1 in 2024. By volume, Merck sits between Lund, Inc. and Mold-masters (2007) Limited.

Merck's three-year grant acceleration

Merck Sharp & Dohme B.V. shows 1 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Merck's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Merck holds 34 patents at rank #9,313, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Merck

By rank, the assignees closest to #9,313 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Merck's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Merck, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Merck ranks #848 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (39 here).

Merck's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 38% higher than 62% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

024681012 20152016201720182019202020212024 1
USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Merck Sharp & Dohme B.V. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 10 29.4%
2016 2 5.9%
2017 7 20.6%
2018 4 11.8%
2019 2 5.9%
2020 2 5.9%
2021 6 17.6%
2024 1 2.9%

Which technologies does Merck Sharp & Dohme B.V. patent most?

Top 15 of 23 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Merck Sharp & Dohme B.V.'s patent record in context - here's where to go next.

  • Merck Sharp & Dohme B.V.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 67.6% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #9,318 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Merck Sharp & Dohme B.V. against Lund, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 39.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.